Not Yet Recruiting
PHASE2
INTERVENTIONAL
NCT07103395
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will enroll patients with locally advanced non-small cell lung cancer (NSCLC). Patients will receive neoadjuvant chemotherapy combined with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin alpha 1, followed by concurrent chemoradiotherapy, and finally consolidation therapy with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin alpha 1. The study aims to evaluate the efficacy and safety of this treatment regimen.
Interventions
Name:
Neoadjuvant therapy
Type:
DRUG
Description:
The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel/pemetrexed, cisplatin, Bevacizumab, iparomlimab and tuvonralimab, and thymosin alpha 1.
Name:
Radiotherapy
Type:
RADIATION
Description:
Definitive dose of hypofractionated radiotherapy was delivered to patients, with concurrent chemotherapy.
Name:
Consolidative therapy
Type:
DRUG
Description:
Consolidation therapy consists of iparomlimab and tuvonralimab and thymosin alpha 1, for a total duration of 1 year.
Primary Outcomes
Measure:
Progression-free survival
TimeFrame:
2-year
Description:
PFS measures the time from the start date of treatment to disease progression, death from any cause or last follow up if alive.
Trial Information
NCT ID
NCT07103395
Status
Not Yet Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Sun Yat-sen University
Last Updated
December 15, 2025